Acetylcholinesterase
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Acetylcholinesterase as ChEMBL target CHEMBL4078, mapped to UniProt O42275. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Acetylcholinesterase matters
Acetylcholinesterase is reviewed as Acetylcholinesterase (UniProt O42275); the current evidence base includes 33 approved drugs, 9325 compounds, and 1451 assays, with lead potency reaching pChEMBL 10.5.
Acetylcholinesterase Sequence length is 633 aa.
Review this target as Acetylcholinesterase, mapped to UniProt O42275. Sequence length is 633 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 33 approved drugs, 9325 compounds, and 1451 assays for this target. The dominant activity type is IC50. CHEMBL32823 is the current potency anchor at pChEMBL 10.5.
Use CHEMBL32823 as the tractability anchor when discussing potency (pChEMBL 10.5).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Acetylcholinesterase matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt O42275, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL32823
|
10.5 | IC50 | — |
|
|
No preferred name
CHEMBL4749763
|
10.4 | Ki | — |
|
|
No preferred name
CHEMBL238756
|
10.2 | Ki | — |
|
|
No preferred name
CHEMBL1161905
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL140476
|
10.1 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
NEOSTIGMINE
CHEMBL278020
|
2013 |
|
|
HYDROQUINONE
CHEMBL537
|
2002 |
|
|
GALANTAMINE
CHEMBL659
|
2001 |
|
|
GALANTAMINE HYDROBROMIDE
CHEMBL1555
|
2001 |
|
|
DONEPEZIL
CHEMBL502
|
1996 |
|
|
DONEPEZIL HYDROCHLORIDE
CHEMBL1678
|
1996 |
|
|
TACRINE
CHEMBL95
|
1993 |
|
|
TACRINE HYDROCHLORIDE
CHEMBL1677
|
1993 |
|
|
ISOFLUROPHATE
CHEMBL1025
|
1957 |
|
|
BERBERINE
CHEMBL295124
|
— |